INTRODUCTION:Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design. METHODS: Patients received 400 mg of sorafenib orally twice daily for two cycles (2 months) (step 1). Responding patients on step 1 continued on sorafenib; progressing patients went off study, and patients with stable disease were randomized to placebo or sorafenib (step 2), with crossover from placebo allowed upon progression. The primary endpoint of this study was the proportion of patients having stable or responding disease 2 months after randomization. RESULTS: There were 299 patients evaluated for step 1; of these, 81 eligible patients were randomized on step 2 and received sorafenib (n = 50) or placebo (n = 31). The 2-month disease control rates after randomization were 54% and 23% for patients initially receiving sorafenib and placebo, respectively, p = 0.005. The hazard ratio for progression on step 2 was 0.51 (95% [confidence interval] CI 0.30, 0.87, p = 0.014) favoring sorafenib. A trend in favor of overall survival with sorafenib was also observed (13.7 versus 9.0 months from time of randomization), hazard ratio 0.67 (95% CI 0.40-1.11), p = 0.117. A dispensing error occurred, which resulted in the unblinding of some patients, but not before completion of the 8-week initial step 2 therapy. Toxicities were manageable and as expected. CONCLUSIONS: The results of this randomized discontinuation trial suggest that sorafenib has single-agent activity in a heavily pretreated, enriched patient population with advanced NSCLC. These results support further investigation with sorafenib as a single agent in larger, randomized studies in NSCLC.
RCT Entities:
INTRODUCTION:Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design. METHODS:Patients received 400 mg of sorafenib orally twice daily for two cycles (2 months) (step 1). Responding patients on step 1 continued on sorafenib; progressing patients went off study, and patients with stable disease were randomized to placebo or sorafenib (step 2), with crossover from placebo allowed upon progression. The primary endpoint of this study was the proportion of patients having stable or responding disease 2 months after randomization. RESULTS: There were 299 patients evaluated for step 1; of these, 81 eligible patients were randomized on step 2 and received sorafenib (n = 50) or placebo (n = 31). The 2-month disease control rates after randomization were 54% and 23% for patients initially receiving sorafenib and placebo, respectively, p = 0.005. The hazard ratio for progression on step 2 was 0.51 (95% [confidence interval] CI 0.30, 0.87, p = 0.014) favoring sorafenib. A trend in favor of overall survival with sorafenib was also observed (13.7 versus 9.0 months from time of randomization), hazard ratio 0.67 (95% CI 0.40-1.11), p = 0.117. A dispensing error occurred, which resulted in the unblinding of some patients, but not before completion of the 8-week initial step 2 therapy. Toxicities were manageable and as expected. CONCLUSIONS: The results of this randomized discontinuation trial suggest that sorafenib has single-agent activity in a heavily pretreated, enriched patient population with advanced NSCLC. These results support further investigation with sorafenib as a single agent in larger, randomized studies in NSCLC.
Authors: Mark J Ratain; Tim Eisen; Walter M Stadler; Keith T Flaherty; Stan B Kaye; Gary L Rosner; Martin Gore; Apurva A Desai; Amita Patnaik; Henry Q Xiong; Eric Rowinsky; James L Abbruzzese; Chenghua Xia; Ronit Simantov; Brian Schwartz; Peter J O'Dwyer Journal: J Clin Oncol Date: 2006-04-24 Impact factor: 44.544
Authors: Egbert F Smit; Anne-Marie C Dingemans; Frederik B Thunnissen; Monique M Hochstenbach; Robert-Jan van Suylen; Pieter E Postmus Journal: J Thorac Oncol Date: 2010-05 Impact factor: 15.609
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Joline S W Lind; Anne-Marie C Dingemans; Harry J M Groen; Frederik B Thunnissen; Otto Bekers; Daniëlle A M Heideman; Richard J Honeywell; Elisa Giovannetti; Godefridus J Peters; Pieter E Postmus; Robert Jan van Suylen; Egbert F Smit Journal: Clin Cancer Res Date: 2010-04-15 Impact factor: 12.531
Authors: Ronan J Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M Steinberg; John J Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone Journal: Clin Cancer Res Date: 2011-01-11 Impact factor: 12.531
Authors: Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz Journal: Oncologist Date: 2007-04
Authors: George R Blumenschein; Ulrich Gatzemeier; Frank Fossella; David J Stewart; Lisa Cupit; Frank Cihon; James O'Leary; Martin Reck Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312
Authors: Marcin Imielinski; Heidi Greulich; Bethany Kaplan; Luiz Araujo; Joseph Amann; Leora Horn; Joan Schiller; Miguel A Villalona-Calero; Matthew Meyerson; David P Carbone Journal: J Clin Invest Date: 2014-02-24 Impact factor: 14.808
Authors: Vassiliki Papadimitrakopoulou; J Jack Lee; Ignacio I Wistuba; Anne S Tsao; Frank V Fossella; Neda Kalhor; Sanjay Gupta; Lauren Averett Byers; Julie G Izzo; Scott N Gettinger; Sarah B Goldberg; Ximing Tang; Vincent A Miller; Ferdinandos Skoulidis; Don L Gibbons; Li Shen; Caimiao Wei; Lixia Diao; S Andrew Peng; Jing Wang; Alda L Tam; Kevin R Coombes; Ja Seok Koo; David J Mauro; Eric H Rubin; John V Heymach; Waun Ki Hong; Roy S Herbst Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: Fan Luo; Zhonghan Zhang; Kunlun Liao; Yang Zhang; Yuxiang Ma; Zhihuang Hu; Kangmei Zeng; Yan Huang; Li Zhang; Hongyun Zhao Journal: Ann Transl Med Date: 2019-06